|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
The PI3K/AKT/mTOR pathway is frequently overactivated in endometrial cancer (EC).
|
30853360 |
2019 |
|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
MiR-101 reduces cell proliferation and invasion and enhances apoptosis in endometrial cancer via regulating PI3K/Akt/mTOR.
|
29081412 |
2017 |
|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, our findings suggest that PIK3CB/p110β contributes to some of the pleiotropic functions of PI3K in endometrial cancer, particularly in the early steps by contributing to cell proliferation.
|
28002804 |
2017 |
|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer.
|
30574817 |
2019 |
|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
We assessed the sensitivity of endometrial cancer cell lines to PARP inhibitors (olaparib and BMN-673) and a PI3K inhibitor (BKM-120), alone or in combination, in the context of their PTEN mutation status.
|
28886696 |
2017 |
|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, we identified that CCL18 derived from TAMs upregulated KIF5B expression to promote EMT via activating the PI3K/AKT/mTOR signaling pathway in endometrial cancer.
|
30779215 |
2019 |
|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results support the notion that the PI3K signaling pathway might be activated, both dependent- and independently of PIK3CA mutations, an aspect that should be considered when designing PIK3 pathway targeting strategies in endometrial cancer.
|
28860563 |
2017 |
|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Endometrial cancers display hyperactivation of the MAPK and PI3K pathways, the result of somatic aberrations in genes such as <i>FGFR2, KRAS, PTEN, PIK3CA</i>, and <i>PIK3R1</i> The FGFR2 and PI3K pathways, have emerged as potential therapeutic targets in endometrial cancer.
|
28119489 |
2017 |
|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
PI3K pathway dependencies in endometrioid endometrial cancer cell lines.
|
23674493 |
2013 |
|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Focusing on ARID1A, we integrated mutation profiles with functional proteomics in 222 endometrial cancer samples, demonstrating that ARID1A mutations frequently co-occur with mutations in the phosphatidylinositol 3-kinase (PI3K) pathway and are associated with PI3K pathway activation. siRNA knockdown in endometrial cancer cell lines increased AKT phosphorylation supporting ARID1A as a novel regulator of PI3K pathway activity.
|
23028188 |
2012 |
|
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Downregulation of PDCD4 induced by progesterone is mediated by the PI3K/AKT signaling pathway in human endometrial cancer cells.
|
31233196 |
2019 |
|
Malignant neoplasm of endometrium
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study analysed the prognostic impact of EGFR family expression in endometrial cancer in relation to PI3K-AKT and MAPK-ERK signalling, as well as drug sensitivity.
|
20664599 |
2010 |
|
Malignant neoplasm of endometrium
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our data suggest that HGF possesses chemotactic ability, has anti-apoptosis action, and induces cellular infiltration via the PI3K/Akt pathway; it also triggers NF-κB activation and up-regulates COX-2 gene expression in endometrial cancer cells.
|
21687953 |
2011 |
|
Malignant neoplasm of endometrium
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The PI3K (phosphatidylinositol-3-kinase)/mTOR (mammalian target of rapamycin) pathway is frequently activated in endometrial cancer through various PI3K/AKT-activating genetic alterations.
|
22662154 |
2012 |
|
Malignant neoplasm of endometrium
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Strikingly, coordinate knockdown of YAP and TAZ, mimicking activation of the HIPPO pathway, markedly decreased both constitutive and growth factor-induced PI3K pathway activation by decreasing levels of the GAB2 linker molecule in endometrial cancer lines.
|
28202507 |
2017 |
|
Malignant neoplasm of endometrium
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer.
|
23702729 |
2013 |
|
Malignant neoplasm of endometrium
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Previous studies have shown that activation of the PI3K-protein kinase B (Akt) signaling pathway has important effects on insulin resistance and endometrial cancer.
|
27613818 |
2017 |
|
Malignant neoplasm of endometrium
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
E2 stimulated cell proliferation and induced GPR30 expression and PI3K/Akt pathway activation in endometrial cancer cells, Ishikawa cells, and HEC-1A cells, whereas the expression of ERs remained unchangeable.
|
23235274 |
2013 |
|
Malignant neoplasm of endometrium
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Somatic loss of phosphatase and tensin homolog (PTEN), a tumor suppressor that counteracts phosphoinositide 3-kinase (PI3K) activity, is one of the most common genetic aberrations in endometrioid endometrial cancer.
|
28945226 |
2018 |
|
Malignant neoplasm of endometrium
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Subsequently, Western blotting was used to detect the expression level of PI3K/AKT in EC.
|
31486482 |
2019 |